Gut microbiome: a novel preventive and therapeutic target for prostatic disease

Front Cell Infect Microbiol. 2024 Jul 29:14:1431088. doi: 10.3389/fcimb.2024.1431088. eCollection 2024.

Abstract

The human gut microbiome (GM) impacts various physiological processes and can lead to pathological conditions and even carcinogenesis if homeostasis is disrupted. Recent studies have indicated a connection between the GM and prostatic disease. However, the underlying mechanisms are still unclear. This review aims to provide a summary of the existing information regarding the connection between the GM and various prostatic conditions such as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), benign prostatic hyperplasia (BPH), and prostate cancer (PCa). Furthermore, the review aims to identify possible pathogenic mechanisms and suggest potential ways of targeting GM to prevent and treat prostatic disease. Due to the complexity of the mechanism between GM and prostatic diseases, additional research is required to comprehend the association between the two. This will lead to more effective treatment options for prostatic disease.

Keywords: benign prostatic hyperplasia; gut microbiome; prostate cancer; prostatitis; therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Gastrointestinal Microbiome*
  • Humans
  • Male
  • Prostatic Diseases / microbiology
  • Prostatic Diseases / prevention & control
  • Prostatic Hyperplasia / microbiology
  • Prostatic Neoplasms / microbiology
  • Prostatitis / microbiology

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by grants from the Jilin Provincial Department of Finance (No: JLSWSRCZX2020-058), Jilin Provincial Department of Science and Technology (No: 20210401154), WU JIEPING Medical Foundation (No: 320.6750.2020-06-37).